ACCESS CHINA Spring Forum
ACCESS CHINA Spring Forum will be held online from March 18th to 19th, 2021.
This conference is the first “CHINA Innovation” themed corporate access event. We expect to host 20 selected Chinese innovative pharma companies looking for global or regional out-licensing opportunities during the 2-day event.
ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations.
ACCESS CHINA collaborates with Life Science Nation (LSN) to launch ACCESS CHINA Spring event during LSN’s Healthtech Partnering Week(HPW). HPW consists of the renowned digital RESI 3-day event, 4D Meets AI 2-day event, and the Longevity, Health & Innovation (LHI) 2-day event.
March 18th-19th 09:00AM-12:00 PM (China time)
March 17th-18th 08:00PM-11:00 PM (Eastern time)
March 18th-19th 08:00AM-11:00 AM (Eastern time)
March 18th-19th 02:00PM-05:00 PM (CET time)
JOIN US WHEN YOU ARE READY
For Global Biopharma Companies
No need to wait for months to spend time and money for a physical event in China. As ACCESS CHINA has several Online Partnering Day events through the year, you are welcome to join us when you are ready.
For Chinese Biopharma Companies
ACCESS CHINA has strong coverage of pharmaceutical and biotech companies from North America, Europe, MENA, Japan, Korea, and etc. This offers you an ideal channel to meet with potential out-licensing or commercial partners in different regions.
During the live showcase held at ACCESS CHINA Online Partnering Day, presenters can discuss their pipeline, R&D activities, fundraising goals, and expectations from China market. Event audiences will come from 2,000+ BD Directors & Executives from biopharma companies and PE/VCs.
For investors missing the live presentations, a replay-day will be arranged. This will give the presenters even broader exposure.